Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Jason Ehrlich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...
/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...
Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) insider Jason Ehrlich sold 2,282 shares of the firm’s stock in a transaction on Friday, June 17th. The shares were sold at an average price of $7.02, for a total transaction of $16,019.64. Following the completion of the transaction, the insider now owns 56,920 shares in the company, […]
Kodiak Sciences (NASDAQ:KOD – Get Rating)‘s stock had its “buy” rating reiterated by equities research analysts at Chardan Capital in a note issued to investors on Monday, Zacks.com reports. Other equities research analysts have also recently issued research reports about the company. Barclays dropped their price objective on Kodiak Sciences from $81.00 to $50.00 and […]